Histone deacetylase inhibitors based on alpha-chalcogenmethylcarbonyl compounds
US7214831B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | May 21, 2003 |
| Grant date | May 8, 2007 |
| Priority date | — |
| Expiry date | May 21, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C49/245
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, for example, an alpha-chalcogenmethylcarbonyl group, such as an alpha-ketothio group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition of histone deacetylase can provide an alternate route for treating cancer, hematological disorders, e.g., hemoglobinopathies, autosomal dominant disorders, e.g. spinal muscular atrophy and Huntington's disease, genetic related metabolic disorders, e.g., cystic fibrosis and adrenoleukodystrophy, or for stimulating hematopoietic cells ex vivo.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.